IDPH--Positive preliminary results for pivotal trial of ID Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Roudy who wrote (1627)	1/18/1999 4:00:00 PM
From: Maurice Winn	1 Recommendation Read Replies (1) of 1762

quote.yahoo.com Looks as though it's time for IDEC to expand their lymphoma franchise with their happily high market capitalization. There would be some decent cost saving by an acquisition of Techniclone quote.yahoo.com No board of directors No Managing Director Less duplication of staff More focus on research, clinical action and FDA approvals instead of leasebacks, letters of credit, options repricing, musical chairs management, fund raising, licensing, buying back marketing rights, investor relations handling, Rubenstein payments and general and administrative costs. Every dollar going into these things is not going into clinical results. More career opportunities for staff to attract better people Marketing synergy when eventually products are approved The lymphoma products are probably synergistic rather than competitive and joint trials are desirable. Stuff like that. Maurice

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next